Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

ImmunoGen, Inc. (IMGN)

5.21   -0.09 (-1.7%) 12-07 16:00
Open: 5.3 Pre. Close: 5.3
High: 5.36 Low: 5.18
Volume: 1,926,585 Market Cap: 1,150(M)

Technical analysis

as of: 2022-12-07 4:23:11 PM
Overall:       
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 6.81     One year: 7.45
Support: Support1: 4.96    Support2: 4.12
Resistance: Resistance1: 5.83    Resistance2: 6.38
Pivot: 5.22
Moving Average: MA(5): 5.33     MA(20): 5.28
MA(100): 5.43     MA(250): 5.24
MACD: MACD(12,26): -0.1     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 34.7     %D(3): 32
RSI: RSI(14): 45.6
52-week: High: 7.76  Low: 3.09
Average Vol(K): 3-Month: 3,651 (K)  10-Days: 2,268 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ IMGN ] has closed above bottom band by 45.9%. Bollinger Bands are 59.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 5.37 - 5.4 5.4 - 5.43
Low: 5.1 - 5.15 5.15 - 5.18
Close: 5.15 - 5.22 5.22 - 5.26

Company Description

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

Headline News

Wed, 30 Nov 2022
ImmunoGen Needs To Make The Most Of Its First-Mover Opportunity (NASDAQ:IMGN) - Seeking Alpha

Mon, 28 Nov 2022
Where Does ImmunoGen, Inc. (IMGN) Stock Fall in the Biotechnology Field After It Is Down -1.15% This Week? - InvestorsObserver

Mon, 28 Nov 2022
Looking Into Immunogen's Return On Capital Employed - Immunogen (NASDAQ:IMGN) - Benzinga

Thu, 24 Nov 2022
ImmunoGen (IMGN) Stock: Ramifications Of Elahere Approval - Seeking Alpha

Mon, 21 Nov 2022
IMGN stock, MRSN stock win buy ratings at Truist on ADC prospects (NASDAQ:MRSN) - Seeking Alpha

Mon, 21 Nov 2022
ImmunoGen Appoints Daniel Char as Senior Vice President and Chief Legal Officer - ImmunoGen, Inc.

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 221 (M)
Shares Float 184 (M)
% Held by Insiders 0.4 (%)
% Held by Institutions 92.6 (%)
Shares Short 17,720 (K)
Shares Short P.Month 13,740 (K)

Stock Financials

EPS -0.59
EPS Est Next Qtl -0.24
EPS Est This Year -0.73
EPS Est Next Year -1.38
Book Value (p.s.) 0.81
Profit Margin (%) -210.4
Operating Margin (%) -204.9
Return on Assets (ttm) -37.4
Return on Equity (ttm) -157.7
Qtrly Rev. Growth 66.9
Gross Profit (p.s.) -0.37
Sales Per Share 0.43
EBITDA (p.s.) -0.88
Qtrly Earnings Growth 0
Operating Cash Flow -215 (M)
Levered Free Cash Flow -109 (M)

Stock Valuations

PE Ratio -8.84
PEG Ratio 0
Price to Book value 6.43
Price to Sales 12.02
Price to Cash Flow -5.34

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.